Drug intelligence / Profile preview

FT-056

Development stage: Preclinical
Lead developer: Blacksmith Medicines
Modality: Small Molecules

Overview

FT-056 is a preclinical small molecule asset initially developed by Forge Therapeutics. It targets antibacterial metalloenzymes and was part of Forge's expertise in antibacterial metalloenzyme targets. Following the merger of Forge Therapeutics with Blacksmith Medicines, the development of FT-056 is continued under the combined Blacksmith Medicines company, which focuses on discovering and developing small molecule therapeutics for infectious diseases, among other areas.

Beyond the preview

Go deeper on FT-056.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FT-056.

Explore the full profile